Related Experiment Videos
The case for beta-blockers as first-line antihypertensive therapy
1Department of Cardiology, Wythenshawe Hospital, Manchester, UK.
Insights
For asymptomatic high blood pressure, only diuretics and beta-blockers effectively prevent heart attack and stroke. These cost-effective medications offer proven benefits for morbidity and mortality in hypertensive patients.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Asymptomatic hypertension treatment aims to prevent cardiovascular events like myocardial infarction, stroke, and heart failure.
- Established evidence supports diuretics and beta-blockers for reducing morbidity and mortality in hypertensive individuals.
- Cost-effectiveness favors diuretics and beta-blockers over newer antihypertensive agents.
Purpose of the Study:
- To review the efficacy and patient-specific benefits of different antihypertensive drug classes.
- To evaluate the impact of diuretics, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors on hard endpoints.
- To differentiate appropriate patient profiles for specific antihypertensive treatments.
Main Methods:
- Review of clinical trial data and established guidelines on antihypertensive treatment.
- Analysis of drug effects on hard endpoints (morbidity, mortality) versus surrogate markers.
- Categorization of drug suitability based on patient demographics and comorbidities.
Main Results:
- Diuretics and beta-blockers are the only drug classes proven to improve hard endpoints in hypertension.
- Diuretics are suitable for elderly patients, especially with isolated systolic hypertension, but may increase cardiac events in younger diabetics.
- Beta-blockers are beneficial for younger and middle-aged patients, particularly white males, and in cases of ischemia or stress, reducing myocardial infarction and stroke incidence.
Conclusions:
- Diuretics and beta-blockers offer proven benefits and cost-effectiveness for managing asymptomatic hypertension.
- Patient profiling is crucial; diuretics suit elderly patients, while beta-blockers are ideal for younger/middle-aged individuals, especially with cardiovascular risk factors.
- Angiotensin-converting enzyme (ACE) inhibitors show value in specific conditions like left ventricular dysfunction and diabetic nephropathy.
Abstract:
REASON FOR TREATMENT: In patients with asymptomatic high blood pressure, antihypertensive treatment is initiated for only one reason, to prevent the hypertensive sequelae of myocardial infarction, stroke and heart failure. MORBIDITY, MORTALITY AND SURROGATE ENDPOINTS: Only diuretics and beta-blockers have been shown to benefit hypertensive patients in terms of the hard endpoints morbidity and mortality. beta-Blockers and diuretics are cheaper than newer drugs and thus represent good value for money. It is not acceptable to use drug effects on plasma lipids or insulin resistance as measures of the effects on coronary heart disease, since dihydropyridine calcium antagonists improve these parameters while significantly increasing coronary heart disease events in the acute and chronic ischaemic situation. PATIENT PROFILING: Diuretics. Diuretics appear particularly suited to elderly hypertensives, especially those with isolated systolic hypertension, but they may increase cardiac events in younger and middle-aged diabetic and non-diabetic hypertensives. Angiotensin converting enzyme (ACE) inhibitors. ACE inhibitors are undoubtedly valuable in the presence of left ventricular dysfunction, and possibly in the diabetic in maintaining good renal function. beta-Blockers. beta-Blockers are particularly well suited to younger and middle-aged hypertensives at all blood pressure levels, especially white males; where ischaemia and/or stress is a factor, beta-blockers can significantly reduce the incidence of myocardial infarction and strokes. beta-Blockers benefit elderly hypertensives by preventing strokes and may prevent coronary heart disease if prescribed with a diuretic.